Reuters logo
Ablynx, Merck Serono sign research alliance
September 26, 2013 / 5:46 AM / 4 years ago

Ablynx, Merck Serono sign research alliance

BRUSSELS, Sept 26 (Reuters) - Belgian biopharmaceutical company Ablynx and Merck Serono said on Thursday they had expanded their ties with the creation of a research alliance that could lead to the development of at least four agents to treat disease.

Merck Serono, the biopharma division of Merck KGaA , will fund a discovery group at Ablynx and the two will jointly select disease targets. The Ablynx team will seek to identify tiny nanobodies to tackle these during a four-year alliance.

Merck Serono will provide 25 million euros ($33.77 million)in funding over the first four years, including an initial payment of 11.5 million euros. ($1 = 0.7403 euros) (Reporting By Philip Blenkinsop)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below